Multidrug-resistant tuberculosis (MDR-TB) refers to the case when a clinical TB isolate is resistant to two of the most potent tuberculosis medications: isoniazid and rifampin. Globally, there are about half a million new cases of MDR-TB per year. Prof. Timothy Rodwell (UC San Diego, San Diego, CA, US) talked to us about the advantages, efficacy and cost-effectiveness of next-generation sequencing in making treatment decisions for patients with drug resistant TB.
‘Shedding Light on New MDR-TB Treatment Decisions with Next Generation Sequencing’ was presented at the annual International Conference on Emerging Infectious Diseases (ICEID), August 7–10, 2022.
- What are the advantages of next-generation sequencing in making treatment decisions in tuberculosis (MDR-TB)? (00:22)
- What clinical evidence supports the efficacy of next-generation sequencing in treatment decisions in tuberculosis? (02:23)
- What clinical evidence supports the cost-effectiveness of next-generation sequencing in treatment decisions in tuberculosis? (05:02)
Disclosures: Timothy Rodwell serves as a consultant for FIND; he receives grant/research support from NIH, DoD; he is a major stock shareholder in Verus Diagnostics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.
Filmed as a highlight of ICEID 2022.
Share this Video
Related Videos In Bacterial Infections
Prosthetic joint infections – advances in diagnosis and treatment approaches: Robin Patel, ECCMID 2023
Prosthetic joint infections (PJI) are difficult to treat and require a multidisciplinary approach including surgical and therapeutic approaches to overcome infection. We were delighted to speak with Dr. Robin Patel (Mayo Clinic, Rochester, MN, USA) to learn more around the incidence, pathogenesis, and prognosis of PJI, the challenges in diagnosis and treatment of PJI and […]
Clostridioides difficile infection in paediatric patients: unmet needs and future challenges: Anne J. Gonzales-Luna, ECCMID 2023
Clostridioides difficile infection (CDI) is usually associated with older age; however, is becoming more prevalent in paediatric patients often in concurrence with comorbidities. There remains many unmet needs in the diagnosis and treatment of CDI in paediatric patients, with the mainstay of treatment being antibiotics. touchINFECTIOUS DISEASES spoke with Dr. Anne J. Gonzales-Luna (University of […]
Kayla Stover Hielscher, IDWeek 2022: Ceftriaxone as a treatment option for MSSA, ensuring optimum activity
Ceftriaxone is frequently used to treat methicillin-susceptible Staphylococcus aureus (MSSA). In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss advantages and limitations of the use of ceftriaxone for the treatment of MSSA, and the data that exists to support its use […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!